Editorial
Los trabajos y opiniones que aquí se exponen son orientadores de lo que se publica en Cuba y en el mundo sobre aspectos relevantes de la hipertensión arterial.
Por: Paul Muntner PhD, Emily B. Levitan PhD, Amy I. Lynch PhD, Lara M. Simpson PhD, Jeffrey Whittle MD, Barry R. Davis MD, PhD, John B. Kostis MD, Paul K. Whelton MD y Suzanne Oparil MD. The Journal of Clinical Hypertension, volume 16, Issue 5, pages 323–330, May 2014.
Few randomized trials have compared visit-to-visit variability (VVV) of systolic blood pressure (SBP) across drug classes. The authors compared VVV of SBP among 24,004 participants randomized to chlorthalidone, amlodipine, or lisinopril in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). VVV of SBP was calculated across 5 to 7 visits occurring 6 to 28 months following randomization. The standard deviation (SD) of SBP was 10.6 (SD=5.0), 10.5 (SD=4.9), and 12.2 (SD=5.8) for participants randomized to chlorthalidone, amlodipine, and lisinopril, respectively
Comentarios recientes